GlassScriptPhysician profile
Shrey Gole
NPI 1457975682
$2,752.45
in general payments reported to CMS, 2019-2025
12 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.50 · 2024: $2,047 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Travel and Lodging: $1,000 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.96 |
| Travel and Lodging | $1,000.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,125.00 | 2024 | Benlysta |
| Abbvie INC. | $752.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $175.28 | 2024-2025 | Saphnelo |
| Amgen INC. | $133.54 | 2024-2025 | Tavneos |
| Aurinia Pharma U.S., INC. | $125.10 | 2024 | Lupkynis |
| Ucb, INC. | $124.99 | 2024 | Bimzelx |
| Genzyme Corporation | $114.77 | 2025 | |
| Janssen Biotech, INC. | $99.99 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $42.78 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2021 | |
| Lilly USA, LLC | $22.27 | 2021 | |
| Kci USA, INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrey Gole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.